title: Betahistine or Cinnarizine for treatment of Meniere's disease.
abstract: BACKGROUND
  Meniere's disease is a condition with sudden attacks of vertigo with nausea and vomiting accompanied by loss of hearing and buzzing sensation in the ears, most commonly unilateral. The exact cause of the disease is unknown. Betahistine is the analogue of histamine with weaker agonistic effect on histamine H1 receptors and stronger effect on histamine H3 receptors, while Cinnarizine has more effective effect on H1 receptors.
  
  
  OBJECTIVE
  The aim is to determine which drug is more effective in the treatment of Meniere's disease Betahistine or Cinnarizine.
  
  
  METHODS
  This study evaluates the effectiveness of Betahistine in 37 patients with the Meniere's syndrome accompanied by classic triad of symptoms treated in hospital conditions and Cinnarizine effect in 36 patients with a less severe clinical picture, which were treated as outpatients. To all patients were conducted laboratory tests, brain CAT (to exclude possible expansive process, MS or stroke) and TCD in order to eliminate any possible circulatory disturbances in VB basin. Group with classic Meniere's syndrome was treated at a dose of Betahistine of 3 x 16 mg and followed 8 weeks, while the second group was treated with Cinnarizine at a dose of 2 x 75 mg and also followed for 8 weeks.
  
  
  CONCLUSIONS
  Already after one month of therapy was noticed better effect in case of Betahistine in terms of symptoms reduction compared to the Cinnarizine effect.
authors: Neurology Clinic, Clinical Center of Sarajevo University, Bolnicka 25, 71000 Sarajevo, Bosnia and Herzegovina. jasminka000@bih.net.ba
authors: Jasminka
authors: J
authors: Djelilovic-Vranic
authors: Azra
authors: A
authors: Alajbegovic
authors: Merita
authors: M
authors: Tiric-Campara
authors: Aida
authors: A
authors: Volic
authors: Zehra
authors: Z
authors: Sarajlic
authors: Eldina
authors: E
authors: Osmanagic
authors: Ljubica
authors: L
authors: Todorovic
authors: Omer
authors: O
authors: Beslagic
mesh_terms: D000328:Adult; D001621:Betahistine / Q000627:therapeutic use*; D002936:Cinnarizine / Q000627:therapeutic use*; D005260:Female; D017442:Histamine Agonists / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy*; D008875:Middle Aged
chemical_list: D017442:Histamine Agonists; D006634:Histamine H1 Antagonists; D002936:Cinnarizine; D001621:Betahistine